QuidelOrtho (NASDAQ:QDEL) Shares Down 7.5% – What’s Next?
by Teresa Graham · The Cerbat GemQuidelOrtho Corporation (NASDAQ:QDEL – Get Free Report) was down 7.5% during mid-day trading on Monday . The company traded as low as $12.63 and last traded at $12.6450. Approximately 499,750 shares changed hands during trading, a decline of 73% from the average daily volume of 1,825,782 shares. The stock had previously closed at $13.67.
Analysts Set New Price Targets
QDEL has been the topic of several research reports. Citigroup lowered their price objective on shares of QuidelOrtho from $30.00 to $13.00 and set a “neutral” rating on the stock in a research report on Wednesday, May 6th. Weiss Ratings restated a “sell (e+)” rating on shares of QuidelOrtho in a research note on Tuesday, April 21st. Wall Street Zen lowered shares of QuidelOrtho from a “hold” rating to a “sell” rating in a research note on Saturday. UBS Group reaffirmed a “neutral” rating and issued a $12.00 price target on shares of QuidelOrtho in a report on Thursday, May 7th. Finally, Zacks Research upgraded QuidelOrtho from a “strong sell” rating to a “hold” rating in a research note on Monday, June 15th. Four analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Reduce” and a consensus target price of $14.88.
View Our Latest Research Report on QuidelOrtho
QuidelOrtho Stock Up 1.9%
The stock has a 50 day moving average of $12.72 and a 200-day moving average of $20.56. The firm has a market capitalization of $829.82 million, a P/E ratio of -0.68 and a beta of 0.77. The company has a debt-to-equity ratio of 1.33, a quick ratio of 0.80 and a current ratio of 1.43.
QuidelOrtho (NASDAQ:QDEL – Get Free Report) last issued its earnings results on Tuesday, May 5th. The company reported ($0.04) earnings per share for the quarter, missing analysts’ consensus estimates of $0.37 by ($0.41). The business had revenue of $619.80 million for the quarter, compared to the consensus estimate of $665.23 million. QuidelOrtho had a positive return on equity of 4.25% and a negative net margin of 45.57%.QuidelOrtho’s revenue for the quarter was down 10.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.74 EPS. QuidelOrtho has set its FY 2026 guidance at 1.800-2.000 EPS. Research analysts predict that QuidelOrtho Corporation will post 1.83 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently bought and sold shares of QDEL. Global Retirement Partners LLC raised its holdings in QuidelOrtho by 3,691.7% during the 4th quarter. Global Retirement Partners LLC now owns 910 shares of the company’s stock valued at $26,000 after acquiring an additional 886 shares during the period. Camelot Portfolios LLC bought a new position in shares of QuidelOrtho in the fourth quarter worth $29,000. Hantz Financial Services Inc. boosted its holdings in shares of QuidelOrtho by 50.3% in the fourth quarter. Hantz Financial Services Inc. now owns 1,082 shares of the company’s stock worth $31,000 after acquiring an additional 362 shares during the period. Larson Financial Group LLC grew its position in shares of QuidelOrtho by 322.2% in the third quarter. Larson Financial Group LLC now owns 1,330 shares of the company’s stock valued at $39,000 after purchasing an additional 1,015 shares in the last quarter. Finally, Leonteq Securities AG grew its position in shares of QuidelOrtho by 555.2% in the first quarter. Leonteq Securities AG now owns 3,466 shares of the company’s stock valued at $57,000 after purchasing an additional 2,937 shares in the last quarter. 99.00% of the stock is owned by institutional investors.
QuidelOrtho Company Profile
QuidelOrtho is a global diagnostics company formed through the merger of Quidel Corporation and Ortho Clinical Diagnostics. The combined entity develops, manufactures and markets a broad portfolio of rapid and high-throughput diagnostic solutions across immunoassay, molecular diagnostics and transfusion medicine. Its offerings span point-of-care platforms for acute care testing as well as large-scale automated systems designed for clinical laboratories and blood banks.
The company’s product range includes rapid antigen and antibody tests for infectious diseases, molecular assays utilizing nucleic acid amplification technology, and integrated immunodiagnostic analyzers.